EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of Overweight on Response to Dupilumab Treatment in Chronic Rhinosinusitis with Nasal Polyps

Michael Habenbacher, Ulrich Moser iD, Ahmed Abaira, Peter Valentin Tomazic, Peter Kiss iD, Clemens Holzmeister, Jakob Pock, Katharina Walla, Angelika Lang, Alexandros Andrianakis iD

Nutrients · 2024

DOI: 10.3390/nu16172982 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nutrients, 2024. Verfasst von Michael Habenbacher und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, Medical University of Graz, 8036 Graz, Austria. Hauptthemen laut MEDLINE: Nasal Polyps, Sinusitis, Antibodies, Monoclonal, Humanized, Rhinitis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic rhinosinusitis with nasal polyps (CRSwNP) significantly impacts quality of life and often presents therapeutic challenges, with biologics like dupilumab showing promise in managing severe, uncontrolled cases. The aim of this study was to assess the influence of overweight on the effectiveness of dupilumab in patients with uncontrolled CRSwNP. This retrospective study analyzed treatment outcomes of 75 CRSwNP patients receiving dupilumab, categorizing them into underweight/normal-weight (BMI ≤ 24.9 kg/m2) and overweight/obese (BMI ≥ 25 kg/m2) groups. Outcome measures included changes in nasal polyp score (NPS) and sinonasal outcome test (SNOT-22) scores. Results demonstrated that the underweight/normal-weight group experienced significantly greater improvements in NPS and a higher rate of total NPS improvement compared to the overweight/obese group. While SNOT-22 scores improved in both groups, no significant differences were observed. Among patients with comorbid asthma, the underweight/normal-weight subgroup also showed significantly better outcomes, including greater reductions in both NPS and SNOT-22 scores. Multiple regression analysis identified BMI as an independent prognostic factor for NPS outcomes. The findings suggest that overweight/obesity adversely affects the response to dupilumab in CRSwNP, emphasizing the need for personalized treatment strategies considering BMI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nasal PolypsSinusitisAntibodies, Monoclonal, HumanizedRhinitisOverweightBody Mass IndexHumansMaleFemaleRetrospective StudiesMiddle AgedChronic DiseaseAdultTreatment OutcomeObesityAgedQuality of LifeRhinosinusitis

Stichwörter der Autor:innen

CRSwNPbiologicchronic rhinosinusitisdupilumabobesityoverweight

Substanzen

dupilumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Otorhinolaryngology, Medical University of Graz, 8036 Graz, Austria.

ORCID-Profile: Ulrich Moser, Peter Kiss, Alexandros Andrianakis

Zitieren

APA

Habenbacher, M., Moser, U., Abaira, A., Tomazic, P. V., Kiss, P., Holzmeister, C., Pock, J., Walla, K., Lang, A., & Andrianakis, A. (2024). Impact of Overweight on Response to Dupilumab Treatment in Chronic Rhinosinusitis with Nasal Polyps. Nutrients. https://doi.org/10.3390/nu16172982

Vancouver

Habenbacher M, Moser U, Abaira A, Tomazic PV, Kiss P, Holzmeister C, et al. Impact of Overweight on Response to Dupilumab Treatment in Chronic Rhinosinusitis with Nasal Polyps. Nutrients. 2024. doi:10.3390/nu16172982

BibTeX
@article{Habenbacher2024,
  author = {Habenbacher, Michael and Moser, Ulrich and Abaira, Ahmed and Tomazic, Peter Valentin and Kiss, Peter and Holzmeister, Clemens and Pock, Jakob and Walla, Katharina and Lang, Angelika and Andrianakis, Alexandros},
  title = {Impact of Overweight on Response to Dupilumab Treatment in Chronic Rhinosinusitis with Nasal Polyps},
  journal = {Nutrients},
  year = {2024},
  doi = {10.3390/nu16172982}
}
Kostenlos starten →